FDA's Updated Biosimilar Naming Convention Stirs Concern in Industry

In an updated draft guidance on the naming convention of biologics, biosimilars, and interchangeable biosimilars, the FDA announced it no longer intends to retrospectively assign suffixes to already-approved biologics. However, the agency will continue to add distinguishing 4-letter suffixes to the proper names of biological products to ensure “strong pharmacovigilance.”1
The guidance also states that the agency does not intend to add suffixes to the names of transition products, such as insulin. For interchangeable biosimilars, the FDA will designate a proper name that is a combination of the core name and a distinguishing 4-letter suffix that is devoid of meaning.
Dr Gottlieb said in a statement that the draft guidance represents the FDA’s attempt at balancing concerns expressed by industry stakeholders. He noted that the agency recognized that adding suffixes to the names of already-approved biologics would be costly to the health care system.1
“If those costs were to be passed on to patients, that impact would run directly counter to the goals of access and affordability that underlie the biosimilars program,” he said in a press release.1
Regarding the agency’s decision to continue with the suffix naming convention to newly-approved products, Dr Gottlieb explained that, “The naming convention is meant, first and foremost, to ensure patient safety by helping providers and patients properly identify products where it’s important to be able to distinguish between different medicines and different versions of similar or interchangeable products.”1
However, industry stakeholders view the naming convention as problematic and as a hindrance to the biosimilar market. The Biosimilars Forum told The Center for Biosimilars that it considers the updated draft guidance “a direct blow to biosimilars uptake” in the United States. According to The Centers for Biosimilars report, the agency’s reversal in its plan to retrospectively add 4-letter suffixes to already approved biologics will lead to misconceptions that strict pharmacovigilance applies only to biosimilars.2
Christine Simmon, executive director of the Biosimilars Council, a division of the Association for Accessible Medicines (AAM), said in a prepared statement that, “AAM is reviewing the FDA’s new draft guidance on biosimilar naming requirements and will submit comments to the docket. FDA’s current requirement of suffixes presents a significant, artificial barrier to biosimilars that is misaligned with the agency’s own Biosimilars Action Plan and the Trump administration’s commitment to lowering drug prices for American’s patients.”3
Ron Lanton III, Esq, executive director and senior counsel for Frier Levitt Government Affairs, wrote in an email to Specialty Pharmacy Times that the guidance shows the FDA’s commitment to its March 2020 transition, when additional products will be open to the biosimilar and interchangeable pathway.
“I know of several stakeholders with questions about the logistics described within the guidance,” Lanton wrote. “I do think there is an opportunity to address several brewing concerns around this issue via the pending comment period. However, it will be interesting to see how this issue develops, especially in light of Dr Gottlieb’s recent resignation.”
In addition, the FDA is implementing an internal procedure for staff to ensure consistency and transparency in the review process for suffixes. The agency also announced that it is considering its naming convention for vaccine products, too.1
The FDA will receive comments on the draft guidance over the next 60 days and intends to issue a final version in the future.
  1. Statement from FDA Commissioner Scott Gottlieb, MD, on FDA’s steps on naming of biological medicines to balance competition and safety for patients receiving these products [FDA statement]. FDA. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm632870.htm. Accessed March 8, 2019.
  1. Davio K. Developers Call FDA Guidance on Suffixes a “Direct Blow” to Biosimilars. Published March 8, 2019. https://www.centerforbiosimilars.com/news/developers-call-fda-guidance-on-suffixes-a-direct-blow-to-biosimilars. Accessed March 8, 2019.
  2. AAM Statement on FDA Draft Guidance on Biosimilar Naming Requirements. Association for Accessible Medicines. https://accessiblemeds.org/resources/press-releases/aam-statement-fda-draft-guidance-biosimilar-naming-requirements. Accessed March 8, 2019.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

The FDA approved a Prior Approval Supplement for immune globulin intravenous (human), 10% liquid (Bivigam, ADMA Biologics) for patients with primary humoral immunodeficiency disease.
Samsung Bioepis’ etanercept-ykro (Eticovo) was approved to treat all of the indications of the reference product, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Megan E.B. Clowse, MD, talks about potential causes of infertility and precautions for using certain treatments to manage autoimmune disease in pregnant women.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.